Scientific Article
Dean of the College of Education for Pure Sciences, Prof. Dr. Hamida Idan Salman, obtained an acceptance to publish a scientific article tagged with the title (Hydroxychloroquine (HCQ) and COVId-19 infection) by the Scientific Articles Committee at the Presidency of Karbala University after the article fulfilled all publication conditions. (Prof. Dr. Hamida Idan Salman) stated that hydroxychloroquine (HCQ) is an approved 4-aminoquinoline drug that has been used for decades in the treatment of malaria. and rheumatoid arthritis (RA). And also in the treatment of lupus erythematosus (CLE). During the first peak of the disease, HCQ was widely used for epidemic prevention of the coronavirus, as one of the previously approved drugs in other indications is being reused to treat COVID-19 patients. Interest in these AQ-antivirals for the treatment of COVID_19 has increased due to the drug’s inhibitory effect on other coronaviruses, such as SARS-CoV_1. One of the advantages of using HCQ as a drug is that it has several advantages that make it an attractive candidate. Not only is it safe, but it is also considered an effective drug with a wide range of interactions for various microbial and autoimmune diseases, likely due to its ability to modulate the immune system. Additionally, HCQ is an inexpensive drug. Most importantly, it can be used safely for pregnant women. The unwanted side effects of this drug are also mild. They include gastrointestinal symptoms (nausea, vomiting, abdominal pain), along with cutaneous manifestations, and central nervous system symptoms (headache, dizziness, tinnitus, and sleep disturbances). Retinopathy is the most serious side effect of HCQ; However, it is rare that it does occur with prolonged treatment and high doses. However, tight monitoring of dose regulation reduces the incidence of HCQ-induced retinopathy. Another rare side effect, which is primarily cardiovascular and liver disease.
To see the article
